

Vectibix (panitumumab)

Override	Approval Duration
Prior Authorization	1 year

Medication
Vectibix (panitumumab)

APPROVAL CRITERIA:

Requests for Vectibix (panitumumab) may be approved if the following criteria are met:

- I. Individual has a diagnosis of unresectable or metastatic colon, rectal, colorectal, appendiceal, or anal adenocarcinoma and the following are met (Label, NCCN 2A):
 - A. Panitumumab is used as a single agent or as part of combination therapy; **AND**
 - B. One of the following is met:
 1. Extended RAS gene mutation testing determines the tumor is RAS wild-type (RAS wild-type means that the KRAS and NRAS genes are normal or lacking mutations) and individual is using in combination with irinotecan or oxaliplatin or as monotherapy; **OR**
 2. Tumor is determined to be BRAF wild-type and individual is using in combination with irinotecan or oxaliplatin; **OR**
 3. Gene mutation testing has determined the tumor to be BRAF V600E positive and panitumumab is used in combination with encorafenib; **OR**
 4. Gene mutation testing has determined the tumor to be KRAS G12C positive and panitumumab is used in combination with sotorasib or adagrasib.

Requests for Vectibix (panitumumab) may not be approved for the following:

- I. All other indications not included above; **OR**
- II. Treatment of RAS-mutant metastatic colorectal cancer, small bowel or anal adenocarcinoma, **or** when RAS mutation status is unknown; **OR**
- III. In combination with other monoclonal antibodies or anti-VEGF agents (NCCN 2A); **OR**
- IV. Treatment of penile cancer; **OR**
- V. Treatment of squamous cell anal carcinoma; **OR**
- VI. Individual has received prior treatment with cetuximab (cetuximab discontinuation due to adverse reaction is not considered prior treatment).

Note:

Vectibix (panitumumab) has a black box warning for dermatologic toxicity. Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC grade 3 and higher) in 15% of patients receiving Vectibix monotherapy.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2024 URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2024; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2024 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on March 4, 2024.
 - a. Colon Cancer. V1.2024. Revised January 29, 2024.
 - b. Rectal Cancer. V1.2024. Revised January 29, 2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.